Humabs Highlights at a Glance

  • State-of-the-art CellCloneTM discovery platform for rapid Lead Generation
  • Highly promising HBV program
  • Highly promising RSV/MPV program
  • Zika Virus program addressing WHO Public Health Emergency
  • Major commercial opportunities driving substantial increase in value
  • Two successful clinical-stage partnered programs with Novartis and MedImmune validate technology and generate major revenue stream
  • Broad and successful partnership with MedImmune on multiple pathogens
  • Public Health portfolio developed with non-dilutive funding
  • Publications in leading journals, dense news flow from internal, partnered and Public Health portfolios
  • Highly skilled team; state-of-the-art laboratory, open access to the Institute of Research in Biomedicine (IRB), and collaborations with leading research institutions worldwide